MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge numerous intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Major demo aims were being To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although on the list of https://caspofunginacetate66654.win-blog.com/11160690/a-secret-weapon-for-m3541